# US 2025/0085288 A1 · Anti-rna virus particle antibody of hbv

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0085288 A1
- Document ID: US20250085288A1
- Status: Published application
- Kind: A1
- Application number: 18/000,669
- Filed: 2020-06-02
- Published: 2025-03-13
- Earliest claimed: 2020-06-02
- Assignees: RCMG Inc.
- Applicants: RCMG Inc.
- Inventors: Hisashi NARIMATSU; Kiyohiko ANGATA; Hiroyuki YONEYAMA
- Web page: https://patentgrep.com/patent/US20250085288A1

## CPC

- G01N 33/5761: {Hepatitis B}
- C07K 16/082: Hepadnaviridae (F), e.g. hepatitis B virus
- C07K 2317/21: from primates, e.g. man
- G01N 2333/02: Hepadnaviridae, e.g. hepatitis B virus
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

An anti-RNA virus particle antibody of HBV may specifically identify an RNA virus particle of hepatitis B virus (HBV). The antibody may include the CDR sequence in a heavy chain amino acid sequence shown in SEQ ID NO:1, 3, 5, or 7 and CDR sequence in a light chain amino acid sequence shown in SEQ ID NO:2, 4, 6, or 8, or a heavy chain CDR sequence and a light chain CDR sequence each having 70% identity with these.

## Claims

### Claim 1

An anti-RNA virus particle antibody of an hepatitis B virus, which specifically discriminates RNA virus particles of the hepatitis B virus.

### Claim 2 (depends on 1)

The anti-RNA virus particle antibody of claim 1, comprising:
A CDR sequence in a heavy chain amino acid sequence shown in SEQ ID NO:1 and CDR sequence in a light chain amino acid sequence shown in SEQ ID NO:2,
CDR sequence in a heavy chain amino acid sequence shown in SEQ ID NO:3 and CDR sequence in a light chain amino acid sequence shown in SEQ ID NO:4,
CDR sequence in a heavy chain amino acid sequence shown in SEQ ID NO:5 and CDR sequence in a light chain amino acid sequence shown in SEQ ID NO:6,
CDR sequence in a heavy chain amino acid sequence shown in SEQ ID NO:7 and CDR sequence in a light chain amino acid sequence shown in SEQ ID NO:8, or
a heavy chain CDR sequence and a light chain CDR sequence each having 70% identity with these.

### Claim 3 (depends on 2)

The anti-RNA virus particle antibody of claim 2, comprising the CDR sequence in the heavy chain amino acid sequence shown in SEQ ID NO:1 and the CDR sequence in the light chain amino acid sequence shown in SEQ ID NO:2.

### Claim 4 (depends on 1)

The anti-RNA virus particle antibody of claim 1, comprising the heavy chain shown in SEQ ID NO:1 and the light chain shown in SEQ ID NO:2,
the heavy chain shown in SEQ ID NO:3 and the light chain shown in SEQ ID NO:4,
the heavy chain shown in SEQ ID NO:5 and the light chain shown in SEQ ID NO:6,
the heavy chain shown in SEQ ID NO:7 and the light chain shown in SEQ ID NO:8, or
the heavy chain and the light chain each having 70% identity with these.

### Claim 5 (depends on 4)

The anti-RNA virus particle antibody of claim 4, comprising the heavy chain shown in SEQ ID NO:1 and the light chain shown in SEQ ID NO:2.

### Claim 6 (depends on 1)

A detection method of RNA virus particles of HBV, the method comprising:
contacting the antibody of claim 1 with a sample.

### Claim 7 (depends on 6)

The method of claim 6, further comprising:
treating the sample with Dnase.

### Claim 8 (depends on 6)

The method of claim 6, wherein the sample is derived from a patient who is now treating with or has been treated with a nucleic acid analog preparation.

### Claim 9 (depends on 6)

The method of claim 6, wherein the sample is derived from a patient whose suppression of HBV-DNA in blood is confirmed.

### Claim 10 (depends on 1)

A kit for detecting one or more RNA virus particles of HBV, kit comprising:
the antibody of claim 1.

### Claim 11 (depends on 1)

A method for providing data for planning prevention or treatment of HBV, the method comprising:
contacting the antibody of claim 1 with a sample.

### Claim 12 (depends on 1)

A method for screening a medicine for prevention or treatment of HBV, the method comprising:
contacting the antibody of claim 1 with a sample.
